Haleon (HLN) Share Price, News & Analysis

Company Overview

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

Key Stats

• Today's Range: 336.10 to 342.60
• 50-Day Range: 327.10 to 386.60
• 52-Week Range: 325 to 419.50
• Volume: 2.15 billion shs
• Average Volume: 50.53 million shs
• Market Capitalization: £29.93 billion
• P/E Ratio: 18.20
• Dividend Yield: 2.05%
• Price Target: GBX 398.67
• Consensus Rating: Moderate Buy

Haleon Stock Analysis - MarketRank™

Haleon scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Haleon has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Haleon has a consensus price target of GBX 398.67, representing about 17.7% upside from its current price of GBX 338.60.

Amount of Analyst Coverage

Haleon has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Haleon is 18.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.15.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haleon is 18.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.38.

Price to Earnings Growth Ratio

Haleon has a PEG Ratio of 1.49. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haleon has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HLN.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Haleon pays a meaningful dividend of 2.05%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Haleon does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Haleon is 36.76%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Haleon this week, compared to 1 article on an average week.

Search Interest

8 people have searched for HLN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Haleon to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Haleon insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £2,826,188.48 in company stock.

Percentage Held by Insiders

0.01% of the stock of Haleon is held by insiders.

Percentage Held by Institutions

62.21% of the stock of Haleon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/29/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Consumer Goods
• Current Symbol: LON:HLN
• CIK: N/A
• Web: www.haleon.com
• Phone: 44 1932 822000
• Fax: N/A
• Employees: 25,408
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Haleon: GBX 398.67
• High Price Target: GBX 512
• Low Price Target: GBX 335
• Potential Upside/Downside: +18.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 18.50
• Trailing P/E Ratio: 18.20
• Forward P/E Ratio: 17.26
• P/E Growth: 1.49
• Net Income: £1.07 billion
• Net Margins: 12.59%
• Pretax Margin: N/A
• Return on Equity: 6.43%
• Return on Assets: 4.45%

Debt

• Debt-to-Equity Ratio: 52.26
• Current Ratio: 0.92
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: £11.03 billion
• Price / Sales: 2.71
• Cash Flow: GBX 15.34 per share
• Price / Cash Flow: 21.95
• Book Value: GBX 182.02 per share
• Price / Book: 1.85

Miscellaneous

• Outstanding Shares: 8,889,056,000
• Free Float: N/A
• Market Cap: £29.93 billion
• Optionable: Not Optionable
• Beta: 0.25